Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
GSK Canada submits respiratory syncytial virus (RSV) vaccine candidate for regulatory review | ||||||||||||||||||||
By: PR Newswire Association LLC. - 26 Nov 2022 | Back to overview list |
|||||||||||||||||||
MISSISSAUGA, ON, Nov. 25, 2022 /CNW/ - GSK has filed a New Drug Submission (NDS) to Health Canada for its respiratory syncytial virus (RSV) older adult vaccine candidate. If approved, GSK's RSV older adult vaccine candidate has the potential to be the first vaccine available to help protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. Canada's regulatory filing follows regulatory submission acceptances by the US Food and Drug Administration (FDA), the European Medicines Agency and Japan's Ministry of Health, Labour and Welfare. There are currently no RSV vaccines for older adults approved anywhere in the world. RSV outbreaks typically occur in late fall through early spring, peaking during the winter months.i Currently, according to the Public Health Agency of Canada, RSV activity remains above expected levels for this time of year.ii Marni Freeman, Country Medical Director, GSK Canada, said: "RSV has evaded scientists for over 60 years. Today, innovations in structural biology and immunology have brought us closer to finding new ways to help protect people and provide customized solutions. As a global leader in vaccines, with more than 20 commercialized vaccines and 21 vaccine candidates in our pipeline, we are excited for the potential that GSK's RSV vaccine candidate has to help reduce the significant burden of RSV in older adults." Older adults are at a greater risk for severe disease due to age-related decline in immunity and underlying conditions. RSV can exacerbate conditions, including chronic obstructive pulmonary disease (COPD), asthma and chronic heart failure and can lead to severe outcomes, such as pneumonia, hospitalization, and death.iii,iv GSK's RSV older adult vaccine candidate contains a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) combined with GSK's proprietary AS01E adjuvant. The regulatory submission includes important data from the pivotal AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial showing vaccine efficacy and safety against RSV lower respiratory tract disease (LRTD) in adults aged 60 years and older. About the AReSVi-006 trial The GSK proprietary AS01 adjuvant system contains QS-21 Stimulon adjuvant licensed from Antigenics Inc, a wholly owned subsidiary of Agenus Inc. About respiratory syncytial virus (RSV) About GSK
SOURCE GlaxoSmithKline Inc. |
||||||||||||||||||||
|
||||||||||||||||||||
Copyright 2022 PR Newswire Association LLC. | Back to overview list |